Ebanga

Reconstitution Instructions

• Aseptically reconstitute and further dilute EBANGA prior to IV infusion. Do not administer as an IV push or bolus.
• More than one vial may be needed for a full dose. Calculate the dose (mg) based on the patient's actual weight in kg and the number of EBANGA vials required [see Dosage and Administration (2.1)] .
• Prior to reconstitution, allow EBANGA vial(s) to reach ambient temperature (15°C to 27°C [59°F to 81°F]) for approximately 20 minutes. If for any reason reconstitution cannot proceed immediately upon reaching ambient temperature, vials that have NOT been reconstituted may be kept at ambient temperature, protected from light, for no more than 24 hours.
• Immediately upon reaching ambient temperature, use a sterile 10 mL syringe and an 18-gauge needle to withdraw 7.7 mL of Sterile Water for Injection, USP. Insert the needle tip into the EBANGA vial. Holding horizontally, angle the needle down at an approximate 45° angle, above the lyophilized powder, which has a cake-like appearance. Slowly inject the diluent along the wall of the vial and without any air to avoid foaming and bubbles.
• Gently swirl (do NOT shake) for approximately 10 seconds; then set the vial down to rest for at least 10 seconds. Repeat until the cake is dissolved. This may take up to 20 minutes.
• Upon reconstitution, one vial delivers 8 mL of solution that is clear to slightly opalescent and colorless to slightly yellow containing 50 mg/mL of ansuvimab-zykl. Do NOT administer and discard the vial if the reconstituted solution is discolored or contains visible particles.
• Dilute the EBANGA solution immediately upon reconstitution. If needed, the reconstituted solution may be stored refrigerated at 2°C to 8°C (36°F to 46°F), protected from light, for up to 4 hours. This 4-hour window includes time required for further dilution and EBANGA solution should be infused immediately upon further dilution.

Dilution Instructions

• Following reconstitution, EBANGA must be further diluted prior to IV infusion.
  • Use an 18-20 gauge, 1-1.5" needle with an appropriately sized syringe up to 60 mL to perform the dilution steps.
  • Prepare the EBANGA IV dosing solution using an appropriately sized syringe up to 60 mL.
• For patients weighing ≥ 2 kg, prepare the diluent using either a latex-free, di-ethylhexylphthalate (DEHP)-free 0.9% Sodium Chloride Injection USP infusion bag, or latex-free, DEHP-free 5% Dextrose Injection USP infusion bag. For patients weighing 0.5 to < 2 kg use a pump-compatible syringe (Table 1).
  • For adult and pediatric patients, either 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP can be used as the diluent.
  • The total volume of the infusion solution to be administered is based on the patient's body weight and is specified in Table 1.
  For patients weighing 0.5 to < 2 kg:
  • Use a 10 mL syringe compatible with the IV infusion pump.
  • Fill the 10 mL syringe with the appropriate amount of diluent (Table 1).
  • Add the calculated volume of EBANGA to the 10 mL syringe (Table 1).
  • Mix the diluted solution by gentle inversion (3 to 5 times) until admixed. Do not shake.
  For patients weighing ≥ 2 kg:
  • Select a diluent solution infusion bag size of appropriate fill volume based on the patient's body weight (see Table 1).
  • Withdraw and discard from the bag a volume of diluent solution that will leave remaining in the bag the appropriate volume based on the patient's weight (see Table 1). Then add the calculated volume of EBANGA to the bag based on the patient's weight (see Table 1).
    For example, for a 55 kg patient, withdraw and discard 150 mL of diluent from a 250 mL infusion bag. Then add 55 mL of EBANGA to obtain a total infusion volume of 155 mL.
  • Gently invert the IV bag 5 to 10 times until the diluted solution is admixed. Do NOT shake.
• Infuse the EBANGA solution immediately upon dilution. If needed, the diluted infusion solution may be stored refrigerated at 2°C to 8°C (36°F to 46°F), for up to 4 hours. Do not freeze the diluted solution. If refrigerated, allow approximately 20 minutes for the diluted solution to come to ambient temperature prior to use. These time limits include reconstitution time.
  Prepare a medical label including patient weight in kg, date, and time of reconstitution.
• Discard vial(s) and all unused contents.

Administration

• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not administer if discolored or if the vial contains visible particles.
• Do not mix with or administer as an infusion with other medicinal products.
• Prepare the IV infusion line with 1.2 micron in-line filter extension set.
• Administer the IV infusion solution over 60 minutes.
  • The diluted EBANGA IV solution can be infused via a central line or peripheral catheter. Do not administer EBANGA as an IV push or bolus.
  • Do not co-administer other drugs simultaneously through the same infusion line.
  • Infusions may be slowed or stopped if necessary, to alleviate any side effects.
• At the end of the infusion, if a syringe pump was used, then remove the syringe and flush the line with 2 to 5 ml of diluent, but not to exceed the total infusion volume. If an infusion bag was used, replace the empty bag and flush the line by infusing at least 25 mL of the diluent, to ensure complete product administration.

Risk Summary

Zaire ebolavirusinfection is life-threatening for both the mother and fetus and treatment should not be withheld due to pregnancy (see Clinical Considerations) . Available data from the PALM trial in which pregnant women with Zaire ebolavirusinfection were treated with EBANGA demonstrate the high rate of maternal and fetal/neonatal morbidity consistent with published literature regarding the risk associated with underlying maternal Zaire ebolavirusinfection. These data are insufficient to evaluate for a drug associated risk of major birth defects, miscarriage, or adverse maternal/fetal outcome.

Animal reproduction studies with ansuvimab-zykl have not been conducted. Monoclonal antibodies, such as EBANGA, are transported across the placenta; therefore, EBANGA has the potential to be transferred from the mother to the developing fetus.

Clinical Considerations

Risk Summary

The Centers for Disease Control and Prevention recommend that mothers with confirmed Zaire ebolavirusnot breastfeed their infants to reduce the risk of postnatal transmission of Zaire ebolavirusinfection.

There are no data on the presence of ansuvimab-zykl in human or animal milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to ansuvimab-zykl are unknown.